Linked Life Data

11123849

Source:http://linkedlifedata.com/resource/pubmed/id/11123849

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
1
pubmed:dateCreated
2001-1-26
pubmed:abstractText
Hyperhomocysteinemia has emerged as an important risk factor for cardiovascular disease. However, its place in clinical practice is somewhat unclear, due to the lack of clinical trials documenting the benefit of treatment on reducing cardiovascular events. Vitamin therapy, particularly with folic acid, reduces plasma homocysteine significantly and improves other surrogate markers of cardiovascular risk such as endothelial function. Although a consensus is lacking on the right approach to diagnosis and treatment of this risk factor, we have suggested an algorithm based on data from clinical studies. We are optimistic that such an approach will be helpful for the clinician until clinical trials, with cardiovascular events as endpoints, are completed.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Jan
pubmed:issn
1523-3804
pubmed:author
pubmed:issnType
Print
pubmed:volume
3
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
54-63
pubmed:dateRevised
2005-11-16
pubmed:meshHeading
pubmed:year
2001
pubmed:articleTitle
Diagnosis and treatment of hyperhomocysteinemia.
pubmed:affiliation
Section of Endocrinology, Department of Medicine, Tulane University School of Medicine, 1430 Tulane Avenue (SL 53), New Orleans, LA 70112, USA.
pubmed:publicationType
Journal Article, Review